Ganaplacide/ Lumefantrine

Novartis

Legend
Product vision
  • Novel agents in combination for treatment including resistant strains; single-dose potential

 
MoA

  • Not yet determined. Decreased susceptibility to Ganaplacide is associated with mutations in three P. falciparum genes, CARL (cyclic amine resistance locus), UDP-galactose and Acetyl-CoA transporters

 
Key features

Ganaplacide

  • Novel mechanism of action – activity against parasites that are resistant to current drugs

  • Rapid killing of parasites (PCT<48 hours)

  • 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

  • Potential for chemoprotection

Lumefantrine

  • New once-daily formulation

  • Transmission-blocking activity in a Standard Membrane Feeding Assay
Status

  • Phase llb combination study ongoing
Next milestone

  • Phase IIb study completion in 2019
Previously

  • Previous names: KAF156, GNF156. Discovery partnership with Wellcome Trust, Novartis, and the Swiss Tropical and Public Health Institute
MMV Project Director

  • Dr Florian Wartha (interim)